First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Robbrecht, D; Jungels, C; Sorensen, MM; Spanggaard, I; Eskens, F; Fretland, SO; Guren, TK; Aftimos, P; Liberg, D; Svedman, C; Thorsson, L; Steeghs, N; Awada, A

Robbrecht, D (通讯作者)，Erasmus MC, Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.

BRITISH JOURNAL OF CANCER, 2022; 126 (7): 1010

Abstract

Background Interleukin-1 (IL-1) signalling is involved in various protumoural processes including proliferation, immune evasion, metastasis and chemor......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索